Jiyong Liu

机构：Shanghai Medical College of Fudan University, Shandong University of Traditional Chinese Medicine, Fudan University, Fudan University Shanghai Cancer Center, China General Nuclear Power Corporation (China), Huashan Hospital, Zhejiang University, Guangzhou Medical University · ORCID：0000-0003-0444-957X

发表论文 490 篇 · 总被引 9407 次 · h-index 50

代表论文

• Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi‐center real‐world study in China (2025 · Alzheimer s & Dementia · 被引 13)
• Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma (2025 · Human Vaccines & Immunotherapeutics · 被引 5)
• Study on flow dynamics and phase transition characteristics of two-phase ejection in confined small channels (2026 · Physics of Fluids · 被引 4)
• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis (2026 · Cancer · 被引 4)
• Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis (2025 · Frontiers in Pharmacology · 被引 4)
• Engineered Ginseng‐Derived Nanovesicles with MCSP Targeting and Mitochondria‐Directed Prodrug Delivery for Synergistic Immunotherapy of Metastatic Melanoma (2025 · Advanced Functional Materials · 被引 3)